Global EditionASIA 中文双语Français
World
Home / World / Americas

Sinopharm vaccine effective against COVID-19: Argentine health minister

Xinhua | Updated: 2021-04-14 11:57
Share
Share - WeChat
Staff members unload Chinese COVID-19 vaccines at the Ezeiza International Airport, Buenos Aires, Argentina, April 1, 2021. The second batch of China's Sinopharm vaccines arrived in Argentina's capital Buenos Aires to strengthen the country's mass inoculation campaign against COVID-19. [Photo/Xinhua]

BUENOS AIRES - Argentine Health Minister Carla Vizzotti on Tuesday highlighted the efficacy of the vaccine against COVID-19 developed by Chinese pharmaceutical firm Sinopharm.

The Sinopharm vaccine being applied by Argentina has an efficacy similar to the AstraZeneca vaccine and many other vaccines, "which is almost 80 percent," Vizzotti told reporters.

The data on the efficacy of the Sinopharm vaccine "is very good ... What has also been shown is that it seeks to reduce the severity and fatality" of the disease, Vizzotti added.

In February, Argentina authorized the emergency use of the Sinopharm vaccine, underscoring its "safety, immunogenicity and efficacy."

On March 25, it authorized the use of the Sinopharm vaccine for people over 60, with Vizzotti saying via Twitter that "the Phase III trial showed an acceptable profile of immunogenicity, efficacy and safety, (and) no serious adverse events."

Argentina detected its first COVID-19 case on March 3, 2020, and as of Tuesday reported a total of 2,579,000 cases and 58,174 deaths.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US